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Owen Sansom, Deputy Director of the Cancer Research UK
Beatson Institute, began his research career investigating the
molecular mechanisms of apoptosis. Over the course of his work he
has moved progressively into a more translational arena, and the
current focus of his lab is to understand the signalling pathways
underlying colorectal and pancreatic cancers. The Sansom lab uses
mouse models to pinpoint how mutations that commonly occur in
these frequently deadly cancers co-operate to promote
tumorigenesis in vivo. This work has provided many important
insights into the molecular changes associated with intestinal and
pancreatic neoplasia and has revealed new targets for drug
development. Here, Owen tells the stories behind some of his most
exciting breakthroughs, describes the experiences and mentors that
shaped his research interests and style of running a lab, and
discusses the challenges of recapitulating the complexity of cancer
as well as translating preclinical evidence to patient therapies. 
Owen Sansom was born in Eastbourne in 1975. He obtained his BSc
degree in Genetics from the University of Nottingham, UK in 1996,
followed by a Master’s degree in Biology from the University of
Manchester, UK. He then moved to Edinburgh to investigate the role
of DNA-damage-induced apoptosis in cancer, under the supervision
of Alan Clarke and Andrew Wyllie. Continuing his post-doctoral
training in the Clarke lab, Owen made the groundbreaking discovery
of the in vivo role of the tumour suppressor protein APC and Wnt
signalling in intestinal cancer, which formed the foundation of follow-
up work performed in his own group at the Cancer Research UK
(CRUK) Beatson Institute, Glasgow. Since setting up the lab in 2005,
he has helped define the molecular hallmarks of colorectal cancer
(CRC), as well as pancreatic cancer, and has used mouse models to
identify potential therapeutic targets for these aggressive malignancies.
Among his many contributions to the field of cancer biology, Owen
and collaborators showed that stem cells can drive the rapid
development of cancer in the intestinal epithelia, lending weight to the
‘cancer stem cell’ theory. In 2007, Owen received the BACR/
AstraZeneca Young Scientist Frank Rose Award. He is now Deputy
Director of the CRUK Beatson Institute and Fellow of the Royal
Society of Edinburgh. In 2013, he was appointed as a Monitoring
Editor of Disease Models & Mechanisms (DMM). 
Have you always been interested in science, and are you
where you pictured you would be 10 years ago?  
I grew up on a farm and was always interested in nature and how
things work. Growing up I felt I wanted to do something in science
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but wasn’t quite sure exactly which route I would follow.
Academically, I was good at biology but also keen on history, so
spent a bit of time deciding which course I was going to do at
university. I opted for Genetics at the University of Nottingham
because the course offered a good mix of classic molecular biology
alongside theoretical evolutionary genetics. From there I just became
more interested in the topic as I learned more about it. As I moved
from theory to practical science I became more and more engaged. 
When you’re young you’re not 100% sure what you want to do,
and I think a lot of people end up in science after gaining some
initial experience and realising that they’re a good ‘fit’ for it. And
as you switch from theoretical lecture-based science to a practical
scenario you begin to realise whether you are able to do it or not.
Often you get people who are very intelligent but when they go into
a lab they’re a bit of a disaster. In science it can take years for things
to come to fruition and provide answers, and getting used to failing
is something you have to come to terms with really quickly. I’m
pretty stoical when it comes to the pitfalls as well as the successes,
and I feel very lucky to be where I am.  
How did your early training shape your current research
interests? 
During my Master’s degree I worked in labs that were interested in
apoptosis. At the time there was a lot of excitement surrounding this
type of cell death, and I really wanted to learn more about the
process and the signals involved. I ended up in Edinburgh for my
PhD, working with Andrew Wyllie and Alan Clarke. Andrew is one
of the people who, working as a pathologist at the University of
Edinburgh, discovered apoptosis many years ago. Since that initial
discovery, he’d done a lot of the molecular work behind several
milestones, such as uncovering the role of p53 in apoptosis, and so
it was very exciting to be working in his group. Alan was very much
at the forefront of making genetic knockout mice and looking at
how apoptosis affects carcinogenesis in vivo. So, whereas in
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Manchester [for my Master’s degree] I’d been doing molecular
mechanistic studies, in Edinburgh I started thinking more about the
broader picture – how important this process is in cancer and how
we can target it. These are big questions that remain largely
unanswered to this day, and my group is actively working on them.
“In science it can take years for things to
come to fruition and provide answers,
and getting used to failing is something
you have to come to terms with really
quickly”
Was that your first foray into translational science? 
I think we almost fell into translational work, as our models became
good mimics of human cancer and we were very keen to manipulate
pathways in vivo using available drugs, to help advance our
biological understanding of the disease. The translational side of
things was, and still is, very interesting for me, and a lot of our work
is focused on trying to understand fundamental biological processes
and then how they go wrong in cancer. Cancer, as a complex system
to study, is really quite fascinating, and studies using protein
inhibitors, for example, can give insights into the disease but also
the physiological mechanisms in normal cells. The discovery of
drug compounds to use in this kind of study has helped basic
biology immensely, as well as driving translation into the clinic.
We’re interested in colon cancer, and our approach has been to
generate mouse models with mutations in genes that ‘go wrong’ and
use these models to work out what happens downstream of loss of
APC, the tumour suppressor gene that is mutated in 80% of patients.
These models really recapitulate the complexity of human cancer
and so provide a good system for analysing the pathways involved.
Going forward, these models will be important for translational
studies and drug discovery. 
Taking a step back, could you explain why colon cancer is
such an important clinical problem?
There are a number of reasons. It is a very common cancer – there
are literally thousands being diagnosed with the disease every year
– and it’s the third most common cause of cancer-associated death.
When the tumour is small, it is easy to surgically remove and most
colon cancers can be cured by surgery. But, at a late stage,
metastasis to the liver occurs and this is the cause of cancer
mortality. The high incidence of the malignancy and its ability to
spread is why it is such a challenging disease, although recently we
have seen some major improvements in 5-year survival rates for
those late stages, mostly attributable to surgery of metastatic disease.  
In 2009 you published a paper with Hans Clevers and Nick
Barker describing the role of stem cells in the colon. What
was the story behind that study?  
In 2002/2003, I was at a meeting focused on the phenotypes of APC
loss and it was at the time that Hans Clevers’ lab was looking at the
role of β-catenin in stem cells and the gut. Our phenotypes were
very similar – when we deleted APC, what went up was similar to
what went down when they knocked down β-catenin in colon cancer
cell lines. We began chatting and comparing our list of targets, and
started collaborating from there. I was always surprised that Hans
wanted to collaborate with us because his lab was doing so well!   
Around that time we started thinking about the origin of cancer –
a very fundamental and important question. We wanted to work out
whether different cells within the intestine have different capacities
to be transformed.  Hans and Nick had produced a very nice mouse
model that allowed them to target Cre-mediated deletion of APC in
Lgr5-marked stem cells. Together, we found that deletion of APC
caused rapid development of adenomas from these stem cells,
proving that a tumour could form very quickly from a stem cell
route. It showed us that all you need is to lose APC within these
cells to give you a benign tumour very rapidly. The flip side of that
paper was the discovery that targeting APC deletion to non-stem-
cell populations causes very few lesions. One of the nice things
about the paper was this ‘compare and contrast’ result for stem-cell
and non-stem-cell populations – by working with Hans and Nick,
we were able to tackle the question from both sides.   
What are the main implications of the findings?
If we think about the intestinal epithelium as a kind of escalator,
where cells are born at the bottom, divide, differentiate and then fall
off at the top, it is interesting that APC loss can reverse many of
these properties and thus a single mutation can effectively act as a
perfect storm for CRC initiation. Loss of a single tumour suppressor
in a stem cell is sufficient for tumorigenesis.  
One other thing to bear in mind, however, is that colon cancer can
take many years to develop, so you can imagine that cancers that
develop rapidly from stem cells might respond differently to
treatments than cancers that develop via slightly longer routes and
need other mutations to accumulate. Recently, in collaboration with
Florian Greten in Munich, we have been trying to model the
formation of tumours from differentiated populations of the intestine
by adding additional mutations that are common in CRC (e.g. KRAS
mutation) alongside APC mutations.
We know from studies showing that a fibroblast can be turned
into an embryonic stem cell that the plasticity of cells is immense.
Our data (published recently in Cell) show pretty convincingly that
we can form tumours from dedifferentiated populations. The key
now is to apply this to human CRC. It is quite possible that tumours
arising from different cell types, for example differentiated versus
stem cells, may have very different properties. Tumours emerging
from differentiated cells would be exposed to different environments
(such as lower levels of Wnt ligands, higher levels of TGFβ ligands,
closer proximity to bowel microorganisms) that may select for
different mutations to allow tumour progression. 
What are the main advantages of using mouse models to
study the dynamic process of tumorigenesis?
Genetically engineered mouse models allow us to introduce the
same mutations that occur in humans into the mouse, and also into
a small subset of cells. This means we can mimic the cancer process
much better. We’re increasingly recognising the complexity of
cancer; the idea that you need multiple mutations and that, when
cancer therapies fail, resistance emerges, all within a complex
tumour architecture influenced by the immune system and
A MODEL FOR LIFE Disease Models & Mechanisms (2014) doi:10.1242/dmm.017350
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emerges, all within a complex tumour
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neighbouring cells. Genetically engineered mice give us the capacity
to grow complex tumours that co-evolve a vasculature and stroma.
The more we learn about cancer, the more importance we are
placing on the immune system and stromal environment. The
tumour stroma provides masses of signals and growth factors as well
as support structures. Given all these signals flying around, targeting
one pathway or one node is probably never going to be sufficient –
there’s no ‘magic bullet’. We use mouse models to try to work out
how different signalling pathways integrate to arrive at the cancer
state, so we can take a multi-pronged approach to therapy. The
development of 3D organoids by the Clevers group has
revolutionised our in vitro work on the intestine. There is a great
excitement that tumour organoids or spheroids will be excellent for
predicting tumour response but we do have to ensure that we have
the most appropriate stroma so that we can capture the complexity
and difficulty of inhibiting endogenous tumours. 
Mouse models also give us the potential to be able to test the
concept of stratified medicine. One of the biggest aims in clinical
testing at the moment is targeting the therapy to the right patient. We
envisage being able to put the major driver mutations into mice and
saying ‘Ok, I’ve got a tumour that has a mutation in X and Y, does
this really respond as we would predict in this setting?’. This would
be preferable to working on a panel of established cell lines that
might evolve to be very different in culture to a real human tumour.
If you get a really striking result then you can be pretty sure that you
can predict what is going to happen in human clinical trials.
Showing what doesn’t work, i.e. lack of response, is just as
important as showing what does work. With increasing demand for
models that accurately recapitulate cancer and are predictive of drug
response, journals such as DMM become more and more important. 
You’ve mentioned that modelling the complex environment
of the tumour is one of the key challenges in understanding
cancer biology. What would you say are the most urgent
challenges in terms of translation and drug discovery?
Trying to get clinicians and pharmaceutical companies to have
enough confidence in preclinical observations to move from
experimental systems into a clinical trial is still a big challenge. As
we go forward I really hope that we will be using mice less and
people more. I do quite a bit of work on pancreatic cancer, as well
as on colon cancer. There have been recent advances in
chemotherapy for pancreatic cancer, but the disease is still lethal.
Most patients with non-surgically resectable tumours do not survive
for more than 6 months. There are potential benefits of taking highly
robust preclinical observations and moving them swiftly into
patients in this scenario. 
“Trying to get clinicians and
pharmaceutical companies to have
enough confidence in preclinical
observations to move from experimental
systems into a clinical trial is still a big
challenge”
Our biggest challenge as a community is deciding what we think is
good enough and robust enough evidence to take into patients. At
what point can we say ‘yes, our scientific evidence is so strong we
believe this should move forward to the clinic now’? How do we
accelerate this process; how do we come up with a platform or a
decision-making tree that helps us to know when to believe preclinical
data? Related to this is the concept of the irreproducibility of science.
How do we address this and convince the sceptics? I think that it’s
critical to come together as a community, and set up networks where
people are challenging each other sufficiently so that our data are
proven to be robust and reproducible across a number of centres. This
would also mean that we’re all testing our drugs in the same way and
following the same procedures.  
I think we always need to keep an eye on the big picture and
remember why we’re doing what we’re doing. Recently, I had a
look at which clinical trials are currently underway across the UK
and felt that there were a number, particularly with an
immunotherapy and immunological focus, where, as a scientist, you
were scratching your head to understand the rationale. We have to
move to a system where trials are initiated with the strongest
possible preclinical data, and where it is easy for researchers with
striking results from preclinical models to be able to influence
clinical trial design. Currently, it appears that if a well-funded
company wants to run a trial this is relatively straightforward even
if there appears to be little rationale for it. 
From a personal standpoint, what would you say your most
exciting research breakthrough has been?
With science you have lots of highs and lows and you’re generally
most excited about your most recent results. But, reporting the
intestinal phenotype after APC gene deletion as a post-doc in Alan’s
lab probably remains my most exciting result to date. We were the
first group to delete APC in the intestine, and it was incredible to
observe the robust, strong phenotype and then go on to characterise
the pathways that go wrong. Within five days we had managed to
completely rewire intestinal homeostasis. This work kind of founded
my own lab as well as forming the basis of Alan’s lab for a long
time. 
Nowadays, we’re very excited about the mechanisms of co-
operation and synergy between oncogenes and tumour suppressor
genes. We have some very nice recent data (with Professor Anne
Willis) showing that, following APC loss, it is important for the
translational machinery to become more active, so that sufficient
protein is produced to allow APC-deficient cells to retain their
proliferative phenotype. 
I also work in areas that I never thought I would end up focusing
on, such as cancer metabolism.  When you are taken outside your
comfort zone and are finding out amazing things, it can be very
exciting.  Of course, these new questions come with a bit of worry
about all the reading you need to do to get up to speed. But that’s
the other exciting thing – being able to challenge yourself by
moving into new areas and broadening your questions.
You have collaborated quite a lot in your career. Are there
any particular mentors who have influenced your style of
doing research and running a lab?
Alan Clarke is basically one of the most brilliant people I’ve ever
met. He’s very intelligent, very laid back, good fun and I am
inspired by his overall attitude, although I’m not as laid back as
Alan. The set-up in his lab allows people to do amazing work whilst
being in an environment where everyone is happy and works
together. This is what you aspire to as a group leader – you want a
lab where everyone is engaged, so that the ideas are fizzing off
people. Alan has been a strong influence in my career.
I have also done a lot of work with Doug Winton in Cambridge
over the years. Doug’s approach is to do beautiful science, no matter
how long it is going to take.  He has worked out so many important
questions in terms of intestinal stem cells, the neutral drift
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hypothesis of stem cells and also stem cells within tumours. He has
established himself as one of the leaders in the stem-cell field. I
always look forward to reading his work, and as a person he is also
really nice and down-to-earth. Since the initial Nature paper, I have
also continued to work with Hans [Clevers] and Nick [Barker],
which has been very valuable and exciting. 
Finally, Margaret Frame [ex Deputy Director of CRUK Beatson
Institute, now head of the CRUK Edinburgh Cancer Centre] and
Karen Vousden [Director CRUK Beatson Institute] were very
supportive when I set my laboratory up at the Beatson Institute. They
really helped guide me through many of the pitfalls of setting up
your laboratory. Also they set up an excellent collaborative
atmosphere that really helped my group broaden its interests. For
example, Margaret and I decided to move into pancreatic cancer
after a long chat over coffee one day and, with the support of the
institute, we were able to get this going relatively quickly. 
What advice do you pass on to young researchers hoping to
follow in your footsteps?
A scientific career is based on the research that you do and I think
the important thing is to always keep the scientific question in mind
and go where the data takes you. Don’t start with any
preconceptions. No matter what happens, it is just very interesting
to see how your story evolves.  
At a time when we’re all very conscious of getting publications,
I think it’s still important to build a career where you build an area
of research. For example, my laboratory is still working on the APC
gene and using similar models to over 10 years ago; there are still
so many questions to answer and, as new technology develops, you
can learn more.
The other thing is to do what interests you. You never know quite
where your research will take you so you need to be aware of what
is about. You need to read, you need to understand and then you
need to be the one driving your project. You should know your
project much better than anybody else.
“With the review process you have to
become battle-weary, and remember that
even at his best Tiger Woods lost more
golf tournaments than he won – that’s
publishing”
Finally, don’t get too disheartened when your papers are rejected.
It is just one of those things – ignore it and move on. If there is a
very good point that is raised then it is important to address and you
gain from the experience. With the review process you have to
become battle-weary, and remember that even at his best Tiger
Woods lost more golf tournaments than he won – that’s publishing.
Even at your peak you’re going to have more papers rejected than
accepted, so you just have to take what’s useful from the review
process, brush yourself off and submit it somewhere else.  
How do you relax and have fun away from the lab?
Living in Scotland I very much enjoy going to the pubs and going
for meals out. The scenery is wonderful, so I also like going for long
walks. Although I get a bit tired of travelling because I do a lot for
work, I do enjoy seeing new places and see the travel as something
of a perk. So, a walk, a good pint of beer and then a holiday every
now and again.  
DMM greatly appreciates Owen’s willingness to share his unique thoughts and
experiences. He was interviewed by Paraminder Dhillon, DMM Scientific Editor.
This piece has been edited and condensed with approval from the interviewee.
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